Manager TitleAgeSince
President - 2023-12-13
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 2023-12-13
Director/Board Member - 2023-12-13
Date Insider Type Main position Quantity % Market Cap.
23-12-13Issuer sale

Chief Executive Officer

643,595 0.3411%
23-12-13Issuer sale

Chief Operating Officer

474,932 0.2517%
23-12-13Issuer sale

Director

4,585 0.0024%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
-1.03%+5.24%+2.94%+9.41% 50.25B
-0.05%+1.65%+419.14%+621.37% 40.39B
+1.02%+7.60%+27.98%-4.10% 34.38B
-12.92%+8.22%+27.97%+62.70% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+25.84%+0.43% - - 16.64B
-2.45%+3.39%+71.69%+132.47% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+0.29%+8.49%+105.89%+105.89% 13.75B
Average +0.20%+3.64%+84.38%+122.89% 27.33B
Weighted average by Cap. +0.10%+4.10%+95.69%+141.13%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock